m (→Write CVS Access: dev.open-bio.org actually works, code.open-bio.org doesn't seem to.)
|(2 intermediate revisions by 2 users not shown)|
|Line 1:||Line 1:|
=== About CVS ===
=== About CVS ===
Latest revision as of 14:02, 15 November 2010
This page is now obsolete, we migrated from CVS to git.
The Biopython source code is kept under a version control system which allows multiple users from around the world to work on the same code base at the same time. We currently use CVS (Concurrent Versions System) for this purpose.
An hourly updated CVS checkout of Biopython is available at http://biopython.open-bio.org/SRC/biopython
Viewing CVS Sources
Our current development CVS sources are available for viewing via ViewCVS:
The main repository is the biopython directory. You can download these sources by clicking the Download tarball link at the bottom of the page.
Anonymous CVS Access
You can also access a read-only version of the CVS sources using our anonymous CVS server. Directions are available at:
To summarize, first login (password is 'cvs'), then checkout the current code:
cvs -d :pserver:firstname.lastname@example.org:/home/repository/biopython login cvs -d :pserver:email@example.com:/home/repository/biopython checkout biopython
Once this is done, you can at a later date update your local copy with one line from within the biopython directory:
Write CVS Access
Write CVS access is available for Biopython developers. This is normally given on a case by case basis, and the best place to discuss getting write access is on the Biopython Development mailing list. Once you have access, the instructions on BioPerl's CVS wiki page are very helpful. To summarize, checkout the code with this command, substituting your actual username:
cvs -d:ext:USERNAME@dev.open-bio.org:/home/repository/biopython checkout biopython
Migration to Subversion
Most of the other Open Bioinformatics Foundation projects have already migrated from CVS to Subversion (SVN). Biopython has been considering moving from CVS to SVN for a while, but we are currently evaluating moving to Git instead.